title: Ex vivo culture of cord blood CD34+ cells expands progenitor cell numbers, preserves engraftment capacity in nonobese diabetic/severe combined immunodeficient mice, and enhances retroviral transduction efficiency.
abstract: Ex vivo culture of hematopoietic stem/progenitor cells could potentially improve the efficacy of human placental/umbilical cord blood (CB) in clinical hematopoietic stem cell (HSC) transplantation and allow gene transduction using conventional retroviral vectors. Therefore, we first examined the effects of a 7-day period of ex vivo culture on the hematopoietic capacity of CB CD34+ cells. Medium for the ex vivo cultures contained either serum and six recombinant human hematopoietic growth factors (GFs), including Flt-3 ligand (FL), Kit ligand (KL = stem cell factor), thrombopoietin (Tpo), interleukin 3 (IL-3), granulocyte colony-stimulating factor (G-CSF), and interleukin 6 (IL-6), or a serum-free medium containing only FL, KL, and Tpo. After culture under both ex vivo conditions, the total numbers of viable cells, CD34+ cells, colony-forming cells (CFCs), and long-term culture initiating cells (LTC-ICs) were increased. In contrast, the severe combined immunodeficiency (SCID) mouse engrafting potential (SEP) of cultured cells was slightly decreased, as compared with fresh cells. Nevertheless, cultured human CB CD34+ cells were able to generate engraftment, shown to persist for up to 20 weeks after transplantation. We next tested the efficacy of retroviral transduction of cultured cells. Transduced cultured human cells were able to engraft in NOD/SCID mice, as tested 4 weeks after transplantation, and EGFP+CD34+ cells and EGFP+ CFCs were isolated from the chimeras. Thus, although additional improvements in ex vivo culture are still needed to expand the numbers and function of human HSCs, the current conditions appear to allow gene transduction into hematopoietic SCID engrafting cells, while at least qualitatively preserving their in vivo engraftment potential.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Novelli
authors.forename: L
authors.initials: L
authors.lastname: Cheng
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: W
authors.initials: W
authors.lastname: Leung
authors.forename: M
authors.initials: M
authors.lastname: Ramírez
authors.forename: V
authors.initials: V
authors.lastname: Tanavde
authors.forename: C
authors.initials: C
authors.lastname: Enger
authors.forename: C I
authors.initials: CI
authors.lastname: Civin
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D012190:Retroviridae / Q000235:genetics*; D013234:Stem Cells / Q000166:cytology* / Q000276:immunology; D014161:Transduction, Genetic
chemical_list: D018952:Antigens, CD34